¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (2ÀÏÂ÷) : 2022-10-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (2ÀÏÂ÷) : 2022-10-16
±³À°ÀÏÀÚ : 2022-10-16
±³À°Àå¼Ò : ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï ÄÚ¿¢½º Çϸð´Ïº¼·ë ¿Ü  
±³À°ÁÖÁ¦ : 2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ´ëÇÑÇǺΰúÇÐȸ
¿¬¶ôó : 02-3473-0284  
À̸ÞÀÏ : kda@derma.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡   (ÀÏ¹Ý 4Á¡ / Çʼö 2Á¡)  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 26 ½Ã°£ 17ºÐ  
¼¼ºÎ¼ö°­·á : 500,000¿ø      
ºñ°í Á¤È¸¿ø 80,000 / ÁØȸ¿ø 40,000 / ºñȸ¿ø 500,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10-16 Harmony 1+2 08:00~08:03 1. Introduction  Chair() 
±³À°½Ã°£ 10-16 Harmony 1+2 08:03~08:48 2. The importance of targeting type 2 inflammation in atopic dermatitis with dupilumab  Àå¿ëÇö(°æºÏÀÇ´ë) 
Åä·Ð 10-16 Harmony 1+2 08:48~09:00 3. Q&A  () 
±³À°½Ã°£ 10-16 Harmony 1+2 09:00~09:50 1. Drug reactions associated with new chemotherapeutic agents  Á¶¼ºÁø(¼­¿ïÀÇ´ë) 
Åä·Ð 10-16 Harmony 1+2 09:50~10:00 2. Q&A  () 
±³À°½Ã°£ 10-16 Harmony 1+2 10:00~10:50 1. Social contract model for ethical deliberation of healthcare institutes  ÀÌÀÏÇÐ(¿¬¼¼ÀÇ´ë À±¸®¹ýÀÇ·áÇаú) 
Åä·Ð 10-16 Harmony 1+2 10:50~11:00 2. Q&A  () 
±âŸ 10-16 Harmony 3 09:00~09:05 1. Overview  Chair() 
±³À°½Ã°£ 10-16 Harmony 3 09:05~09:20 2. Cutaneous scar: Basics and crucial determinants for a potentially scarless wound healing  ±èÇý¼º(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 3 09:20~09:35 3. A review of hypertrophic scars and keloid and its treatment  À¯È­Á¤(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 3 09:35~09:50 4. A review of atrophic scars and its treatment  ÃÖõÇÊ(ÇϴôÀ³¦ÇǺΰú) 
Åä·Ð 10-16 Harmony 3 09:50~10:00 5. Q&A  () 
±âŸ 10-16 Harmony 3 12:30~12:35 1. Overview  ³ë³«°æ(¸®´õ½ºÇǺΰú) 
±³À°½Ã°£ 10-16 Harmony 3 12:35~12:50 2. Scars of different types and their key pathophysiology  ³ë¹Ì·É(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 3 12:50~13:05 3. Prevention and early intervention of post-surgical scars  ÃÖ¿µÁØ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 3 13:05~13:20 4. Combined surgical and nonsurgical treatment of old white scars  ±¸º»Ã¶(³ªÀ½ÇǺΰú) 
Åä·Ð 10-16 Harmony 3 13:20~13:30 5. Discussion, Q&A  () 
±âŸ 10-16 Harmony 3 13:30~13:32 1. Overview  Chair() 
±³À°½Ã°£ 10-16 Harmony 3 13:32~13:44 2-1. Importance of bystanders such as keratinocyte and fibroblast in vitiligo pathogenesis  À̽ÃÇü(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 3 13:44~13:56 2-2. Insights into vitiligo pathogenesis utilized to create new targeted treatment strategies  Á¤±âÇå(°æÈñÀÇ´ë) 
Åä·Ð 10-16 Harmony 3 13:56~14:01 2-3. Q&A  () 
±³À°½Ã°£ 10-16 Harmony 3 14:01~14:07 3-1. Case presentation (3 cases)  À̱ټö À¯È­Á¤ ³ªÁ¤ÀÓ(¿ìÅÂÇÏÇѽ°æÇǺΰú °í·ÁÀÇ´ë ¼­¿ïÀÇ´ë) 
Åä·Ð 10-16 Harmony 3 14:07~14:30 3-2. Panel Discussion and Q&A  À̱ټö À¯È­Á¤ ³ªÁ¤ÀÓ(¿ìÅÂÇÏÇѽ°æÇǺΰú °í·ÁÀÇ´ë ¼­¿ïÀÇ´ë) 
±âŸ 10-16 Harmony 3 15:00~15:05 1. Overview  Chair() 
±³À°½Ã°£ 10-16 Harmony 3 15:05~15:20 2. Occupational contact dermatitis - diagnosis, causes, and the importance of patch test  ¹æöȯ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 3 15:20~15:35 3. Contact dermatitis related to hobbies - diagnosis, causes, and the importance of patch test  Áֹμ÷(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 3 15:35~15:50 4. APEODS 2022 meeting report - update on contact dermatitis  ÀÌ»óÀº(¿¬¼¼ÀÇ´ë) 
Åä·Ð 10-16 Harmony 3 15:50~16:00 5. Q&A  () 
±âŸ 10-16 Harmony 3 16:00~16:05 1. Overview  Chair() 
±³À°½Ã°£ 10-16 Harmony 3 16:05~16:20 2. The biggest and popular prescribed antibiotic for acne, doxycycline vs. minocycline  ÀÌÈñÁ¤(Â÷ÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 3 16:20~16:35 3. Next generation of tetracyclines and other promising new agents  ¹Ú±Í¿µ(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 3 16:35~16:50 4. Retinoid and anti-androgens for acne treatment  ÃÖÀ¯¼º(¼øõÇâÀÇ´ë) 
Åä·Ð 10-16 Harmony 3 16:50~17:00 5. Q&A  () 
±³À°½Ã°£ 10-16 Harmony 3 10:00~10:17 1. Allergic contact dermatitis (patch test)  °íÁÖ¿¬(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 3 10:17~10:34 2. Genetic skin diseases (IIF mapping, NGS)  ÀÌ»óÀº(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 3 10:34~10:51 3. Autoimmune bullous diseases (IIF, ELISA)  ±èÁ¾ÈÆ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 10-16 Harmony 3 10:51~11:00 4. Q&A  () 
±³À°½Ã°£ 10-16 Vivace 08:30~08:44 1. History and overview  ±è¹®¹ü(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 10-16 Vivace 08:44~09:02 2. Devices: Classic D vs. polarized D  ÀÌ°©¼®(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 10-16 Vivace 09:02~09:20 3. Nail disorder  À̵¿À±(¼º±Õ°üÀÇ´ë) 
Åä·Ð 10-16 Vivace 09:20~09:25 4. Q&A  () 
±³À°½Ã°£ 10-16 Vivace 09:25~09:43 5. Melanocytic skin lesions vs. Melanoma  ¹®Á¦È£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-16 Vivace 09:43~10:01 6. Precancerous lesions - Bowen, Actinic keratosis, etc.  Àå¹Î¼ö(°í½ÅÀÇ´ë) 
±³À°½Ã°£ 10-16 Vivace 10:01~10:19 7. NMSC - Basal cell carcinoma, SCC  ¼­¼öÈ«(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10-16 Vivace 10:19~10:37 8. Benign skin tumors  ±èÈñÁÖ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 10-16 Vivace 10:37~10:55 9. Alopecia and hair disorder  À¯¹Ú¸°(°æÈñÀÇ´ë) 
Åä·Ð 10-16 Vivace 10:55~11:00 10. Q&A  () 
±³À°½Ã°£ 10-16 Allegro 08:00~08:20 1. Connective disease and bullous disease  Áø¼±ÇÊ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-16 Allegro 08:20~08:40 2. Pigmentary, endocrine and metabolic disease  ±Ç¼øÈ¿(°æÈñÀÇ´ë) 
±³À°½Ã°£ 10-16 Allegro 08:40~09:05 3. Urticaria, erythematous and vascular disease  ±è´ëÇö(°í·ÁÀÇ´ë) 
È޽Ġ10-16 Allegro 09:05~09:10 Break  () 
±³À°½Ã°£ 10-16 Allegro 09:10~09:30 4. Benign and malignant tumor of epidermis  ÇÏ´ë·æ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 10-16 Allegro 09:30~09:50 5. Appendageal tumor, melanocytic tumor, tumor of dermis & Subcutaneous fat, lymphoma  ¹éÀ¯»ó(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10-16 Allegro 09:50~10:10 6. Dermatitis due to physical forces, diseases of subcutaneous fat  ¹Ú»óÇö(Àü³²ÀÇ´ë) 
È޽Ġ10-16 Allegro 10:10~10:15 Break  () 
±³À°½Ã°£ 10-16 Allegro 10:15~10:40 7. Laser and cosmetic dermatology  ±èÁ¤Àº(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 10-16 Allegro 10:40~11:00 8. Dermatosurgery  ÃÖÁö¿õ(¾ÆÁÖÀÇ´ë) 
±âŸ 10-16 Harmony 1+2 11:10~11:13 1. Introduction  Chair() 
±³À°½Ã°£ 10-16 Harmony 1+2 11:13~11:58 2. Embracing the Potential of IL-17 inhibitor, from Psoriasis to HS  Dr. Laura Savage(Leeds Teaching Hospitals NHS Trust UK) 
Åä·Ð 10-16 Harmony 1+2 11:58~12:10 3. Q&A  () 
±âŸ 10-16 Harmony 1+2 12:30~12:35 1. Introduction  () 
±³À°½Ã°£ 10-16 Harmony 1+2 12:35~12:55 2. The relationship between air pollution and incidence of atopic dermatitis  ¼­Çö¹Î(ÇѾçÀÇ´ë) 
Åä·Ð 10-16 Harmony 1+2 12:55~13:00 3. Q&A  () 
±âŸ 10-16 Harmony 1+2 13:00~13:05 1. Introduction  () 
±³À°½Ã°£ 10-16 Harmony 1+2 13:05~13:25 2. Cutaneous malassezia: Commensal, pathogen, or protector?  ±èÁ¤Àº(°¡Å縯ÀÇ´ë) 
Åä·Ð 10-16 Harmony 1+2 13:25~13:30 3. Q&A  () 
±³À°½Ã°£ 10-16 Vivace 12:30~12:47 1. Micropunch grafting to complete vitiligo treatment  ¹èÁ¤¹Î(ÈúÇϿ콺ÇǺΰú) 
±³À°½Ã°£ 10-16 Vivace 12:47~13:04 2. Hairline correction surgery using follicular unit extraction  ±è´ë¿ì(¸ð°ÇÇǺΰú) 
±³À°½Ã°£ 10-16 Vivace 13:04~13:21 3. Perfect transconjunctival fat removal without recurrence and bleeding  ±èº´Ã¶(¿¤·¹¸àÆ®ÇǺΰú) 
Åä·Ð 10-16 Vivace 13:21~13:30 4. Q&A  () 
±³À°½Ã°£ 10-16 Vivace 13:30~13:43 1. Cryotherapy for skin tumors  ±èÁØ¿µ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 10-16 Vivace 13:43~13:56 2. Cryotherapy for inflammatory skin diseases  ±èÇý¿ø(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-16 Vivace 13:56~14:09 3. Cryotherapy for cosmetic purpose: Cryolipolysis  °­½ÂÈñ(¸®´õ½ºÇǺΰú) 
±³À°½Ã°£ 10-16 Vivace 14:09~14:22 4. Basics of cooling and cryotherapy: Prevention and management of adverse effects  ÀÌÁ¾Èñ(¼º±Õ°üÀÇ´ë) 
Åä·Ð 10-16 Vivace 14:22~14:30 5. Q&A  () 
±âŸ 10-16 Allegro 12:30~12:33 1. Introduction  Chair() 
±³À°½Ã°£ 10-16 Allegro 12:33~13:03 2. A new era of Atopic dermatitis, What  À̵¿ÈÆ(¼­¿ïÀÇ´ë) 
Åä·Ð 10-16 Allegro 13:03~13:10 3. Q&A  () 
±âŸ 10-16 Allegro 13:10~13:13 1. Introduction  Chair() 
±³À°½Ã°£ 10-16 Allegro 13:13~13:43 2. Avodart; All time favorite in real world!  ÃÖÁö¿õ(¾ÆÁÖÀÇ´ë) 
Åä·Ð 10-16 Allegro 13:43~13:50 3. Q&A  () 
±âŸ 10-16 Allegro 13:50~13:53 1. Introduction  Chair() 
±³À°½Ã°£ 10-16 Allegro 13:53~14:23 2. Efficacy? And safety of trifarotene in patients with facial and truncal acne  ÃÖÈÆ(Á¶¼±ÀÇ´ë) 
Åä·Ð 10-16 Allegro 14:23~14:30 3. Q&A  () 
±âŸ 10-16 Allegro 15:00~15:03 1. Introduction  Chair() 
±³À°½Ã°£ 10-16 Allegro 15:03~15:33 2. Cyclosporine management in dermatology  ±èÁ¤Àº(ÇѾçÀÇ´ë) 
Åä·Ð 10-16 Allegro 15:33~15:40 3. Q&A  () 
±âŸ 10-16 Allegro 15:40~15:43 1. Introduction  Chair() 
±³À°½Ã°£ 10-16 Allegro 15:43~16:13 2. A retrospective analysis of the factors affecting the treatment outcomes of cyclosporine  ÀÌ°¡¿µ(¼º±Õ°üÀÇ´ë) 
Åä·Ð 10-16 Allegro 16:13~16:20 3. Q&A  () 
±³À°½Ã°£ 10-16 Allegro 16:20~16:23 1. Introduction  Chair() 
±³À°½Ã°£ 10-16 Allegro 16:23~16:53 2. DMF, a new oral treatment for moderate-to-severe psoriasis  ¹æöȯ(°¡Å縯ÀÇ´ë) 
Åä·Ð 10-16 Allegro 16:53~17:00 3. Q&A  () 
±³À°½Ã°£ 10-16 Harmony 1+2 13:30~14:20 1. My experience of superficial and subcutaneous mycoses in Gyeongju for 31 years  ¼­¹«±Ô(µ¿±¹ÀÇ´ë) 
Åä·Ð 10-16 Harmony 1+2 14:20~14:30 2. Q&A  () 
±³À°½Ã°£ 10-16 Harmony 1+2 15:00~15:17 1. Bullous disease  ±èÁ¾ÈÆ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 1+2 15:17~15:34 2. Chronic urticaria  ÃÖÁ¾¿ø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-16 Harmony 1+2 15:34~15:51 3. Vitiligo  À̽ÃÇü(¼­¿ïÀÇ´ë) 
Åä·Ð 10-16 Harmony 1+2 15:51~16:00 4. Q&A  () 
±âŸ 10-16 Harmony 1+2 16:00~16:05 1. Introduction  Chair() 
±³À°½Ã°£ 10-16 Harmony 1+2 16:05~16:50 2. Dante, Puccini and their beloved Florence (featuring Bologna Medical School)  À¯Á¤¿ì(Ȳ¼ºÁÖÅÐÅÐÇÑÇǺΰúÀÇ¿ø) 
Åä·Ð 10-16 Harmony 1+2 16:50~17:00 3. Q&A  () 
±âŸ 10-16 Vivace 15:00~15:05 1. Introduction  Chair() 
±³À°½Ã°£ 10-16 Vivace 15:05~15:29 2. Pigment lesion, dermatologist can treat differently  ¾ÈÀμö(¹Ì¼Ò°¡ÀÎÇǺΰú) 
±³À°½Ã°£ 10-16 Vivace 15:29~15:53 3. How can we treat acne (non-pharmacologic treatment)  ¹æÂùÀÏ(ÈÞ¸ÕÇǺΰú) 
±³À°½Ã°£ 10-16 Vivace 15:53~16:17 4. [Skin tightening, Lifting, Contouring, Wrinkles, +¥á] The skills to create opportunities  Á¤¿î°æ(À¯¾ØÁ¤ÇǺΰú) 
±³À°½Ã°£ 10-16 Vivace 16:17~16:41 5. The importance of dermocosmetics and its role in dermatological treatment  ÀÌÇÏÀº(Æ÷·¹ÇǺΰú) 
Åä·Ð 10-16 Vivace 16:41~17:00 6. Q&A  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ (2ÀÏÂ÷) : 2022-10-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦37ȸ ´ëÇѽŰæ°úÀÇ»çȸ Ãß°èÇмú´ëȸ : 2022-10-16
´ÙÀ½±Û °Ç±¹´ëº´¿ø Á¦11ȸ ´ëÇÑ»ýÈ°½À°üº´ÇÐȸ 2022 Ãß°èÇмú´ëȸ : 2022-10-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 45 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 35 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 36 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 44 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 38 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 29 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 12 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 12 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 26 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 14 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 12 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 31 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 23 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 26 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 22 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷